Androgenic AlopeciaPhase 3MATTNCT07435012
Androgenic Alopecia TH07 Clinical Trial
A Phase 3 study testing TH07 and Minoxidil 5% Topical Solution in people with Androgenic Alopecia, run by Triple Hair Inc at 1 site in Canada.
Trial summary
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. Read more about this study
- Who is it for?
- Ages 18 to 49 years, men only
- Conditions the study is for
- Androgenic Alopecia
- What is being tested?
- TH07 and Minoxidil 5% Topical Solution
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 420 participants
- Where
- 1 siteCanada
- Study dates
- Apr 2026to Apr 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Males, 18 to 49 years of age on the date of enrollment.
- Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
- Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
- Not administered any systemic or topical treatment for AGA during the last 90 days.
- Willing to comply with the following restrictions for the duration of trial participation:
- Any systemic or topical treatment of any system of medicine (other than trial treatment) for AGA.
Show all 18Show fewer
- Hair dyes, hair texturizers, relaxers etc.
- Any new vitamins or nutritional supplements that are currently not being administered.
- Tattooing in the trial target area.
- Blood donations.
- OTC hair restorers.
- Do not expose your pregnant partner to your hands/skin where the drug might be present.
- Participation in any other drug or device trials during the course of this trial.
- Note: However, the following shall be permissible:
- Non-medicated \& anti-dandruff shampoos, scalp/hair applications including styling gels, sprays, mousse (styling gels, sprays, mousse etc. not to be used on the days of trial visits to the clinic.
- Current regimen (if any) of vitamins and nutritional supplements.
- Willing and able to provide written informed consent for participation in the trial and to comply with all trial requirements.
- Availability of and usage familiarity with a personal mobile phone (Android or iOS) with internet connectivity and a personal email address.
Who cannot join
- History of scalp treatment including though not limited to any of the following:
- Hair transplant or extension surgery.
- Hair weaving.
- Laser or light therapy on the scalp in the last 6 months.
- Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.
- 5-Any other surgical treatment for hair loss
Show all 14Show fewer
- Any of the following hair styles:
- 1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
- Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
- Any other significant abnormalities indicating of severe, acute or chronic medical condition(s) that may lead to hair loss or otherwise interfere with the interpretation of trial results.
- History or likelihood of use of any of the specified medicines.
- History or clinical diagnosis of any of the specified medical conditions.
- Participation in any investigational or marketed drug or device trial in the last 90 days prior to screening for this trial.
- Any other condition that in the opinion of the investigator makes the patient unsuitable for inclusion in the trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Lori Hebert contact
Canada1 site, 1 recruiting
- Recruiting
YVR Aesthetic Training and Study Centre.
Vancouver, British Columbia, V5Z1H2
Janette Sen, 604-729-1911, janette@yvrtrainingcentre.com
About this study
Official title: Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Read the detailed description
The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.
TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.
Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.
The treatment will be applied daily (once or twice) for 24 weeks.
- Conditions
- Androgenic Alopecia
- Being tested
- TH07, Minoxidil 5% Topical Solution, Placebo
- Keywords
- Hair Loss, Hair growth, Androgenic Alopecia, Balding
- Medical subject headings
- Alopecia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TH07Drug
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day
TH07Drug
- TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day
- Placebo; topical solution; once a day
Minoxidil 5% Topical SolutionDrug
Minoxidil 5%; topical solution; twice a day
PlaceboOther
Placebo; topical solution; twice a day
| Study group | Role | What they receive |
|---|---|---|
| Arm A | Experimental | All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks Receives: Drug: TH07 |
| Arm B | Experimental | All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks Receives: Drug: TH07 |
| Arm C | Active comparator | All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks Receives: Drug: Minoxidil 5% Topical Solution |
| Arm D | Placebo comparator | All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Non-vellus hair count
Number of hair in the matched target area measured by phototrichogram
Measured: Baseline and week 24
Secondary outcomes (4)
Hair diameter and cumulative hair thickness
hair thickness is defined as average hair diameter * hair count in the matched target area / size of matched target area (mm/cm2)
Measured: Baseline and week 24
Subject-reported improvement
self-assessment questionnaire
Measured: week 24
Non-vellus hair count
in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo
Measured: Baseline and week 24
Incidence of treatment related adverse events.
reporting of adverse events and serious adverse events
Measured: through study completion, average 28 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Androgenic AlopeciaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 420 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Triple Hair Inc
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07435012
- Sponsor's protocol ID
- TH0701
- Acronym
- MATT
- Status last verified
- Mar 2026
- First submitted
- 18 Feb 2026
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.
- ClinicalTrials.gov ID
- NCT07435012
- Acronym / sponsor ID
- MATT / TH0701
- Conditions
- Androgenic Alopecia
- Keywords
- Hair Loss, Hair growth, Androgenic Alopecia, Balding
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 420 participants (estimated)
- Lead sponsor
- Triple Hair IncIndustry (pharma, biotech, devices)
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Detailed description
The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.
TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.
Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.
The treatment will be applied daily (once or twice) for 24 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Arm A | Experimental | Drug: TH07All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks |
| Arm B | Experimental | Drug: TH07All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks |
| Arm C | Active comparator | Drug: Minoxidil 5% Topical SolutionAll participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks |
| Arm D | Placebo comparator | Other: PlaceboAll participants in Arm D will apply Placebo topical solution twice a day for 24 weeks |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (18 listed)
- Males, 18 to 49 years of age on the date of enrollment.
- Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
- Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
- Not administered any systemic or topical treatment for AGA during the last 90 days.
- Willing to comply with the following restrictions for the duration of trial participation:
Key exclusion criteria (14 listed)
- History of scalp treatment including though not limited to any of the following:
- 5-Any other surgical treatment for hair loss
- Any of the following hair styles:
- 1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
- Known or presumed hypersensitivity to any trial treatment medication; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of investigator may affect the outcome of trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TH07TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day | Drug | Arm A |
| TH07* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day | Drug | Arm B |
| Minoxidil 5% Topical SolutionMinoxidil 5%; topical solution; twice a day | Drug | Arm C |
| PlaceboPlacebo; topical solution; twice a day | Other | Arm D |
Primary outcome
Non-vellus hair count
Time frame: Baseline and week 24
Number of hair in the matched target area measured by phototrichogram
4 secondary outcomes
Hair diameter and cumulative hair thickness
Time frame: Baseline and week 24
Subject-reported improvement
Time frame: week 24
Non-vellus hair count
Time frame: Baseline and week 24
Incidence of treatment related adverse events.
Time frame: through study completion, average 28 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Androgenic Alopecia
Not yet recruitingPhase 2
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Androgenetic Alopecia
RecruitingPhase 1/2
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
RecruitingPhase 2/3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Androgenetic Alopecia
Enrolling by invitation
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
Androgenic Alopecia, Hair Loss/Baldness
Recruiting
A Split-Scalp Study Evaluating the Efficacy and Safety of Fractional Laser Therapy With and Without Exosomes in the Treatment of Androgenetic Alopecia
Androgenetic Alopecia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lori Hebert contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing TH07 and Minoxidil 5% Topical Solution in people with Androgenic Alopecia, run by Triple Hair Inc at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 18 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Edouard AL-Chami (647-453-3253, ealchami@triplehair.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Non-vellus hair count (time frame: Baseline and week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.